- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.03. | Maze tumbles on positive data for kidney disease drug | ||
| 25.03. | Beam posts positive data on base editing treatment for AATD | ||
| 25.03. | Sarepta sees early success with RNAi drugs from Arrowhead | ||
| 25.03. | Merck to buy Terns in $6.7B bet on a 'differentiated' leukemia drug | ||
| 24.03. | RA Capital targets China with latest SPAC deal | ||
| 24.03. | Immutrin raises $87M to advance drug for progressive heart disease | ||
| 24.03. | Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases | ||
| 24.03. | Karyopharm myeloma drug yields mixed data in myelofibrosis trial | ||
| 24.03. | How former Acorda CEO Ron Cohen landed at a Parkinson's cell therapy startup | ||
| 23.03. | Apogee strengthens case for longer-lasting eczema drug | ||
| 23.03. | Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results | ||
| 23.03. | FDA seeks feedback on voucher program; Study data lift 'overhang' on Insmed shares | ||
| 23.03. | Risk, readiness and resilience | ||
| 20.03. | Earendil Labs, an AI-powered drugmaker, hauls in $787M | ||
| 20.03. | Roche stops work on experimental SMA drug | ||
| 20.03. | Novartis pays $2B to land a startup's breast cancer drug | ||
| 20.03. | Rhythm obesity drug wins broader use from FDA | ||
| 19.03. | Novo uses FDA voucher to win speedy approval of higher-dose Wegovy | ||
| 19.03. | Lilly's three-pronged obesity drug hits goal in large diabetes trial | ||
| 19.03. | Pfizer aims for wider use of PARP drug in prostate cancer with new data | ||
| 19.03. | A biotech VC sees early signs of a turnaround for startups | ||
| 19.03. | AstraZeneca to boost cell therapy capabilities with new China investment | ||
| 18.03. | RBC: Revolution, Xenon, Arrowhead among top takeover targets | ||
| 18.03. | J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections | ||
| 18.03. | Aspen's fresh Parkinson's data; Aldeyra tanks following FDA rejection |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.